Sign in
TerminatedPhase 2

Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant

Key facts

Who runs it
Sanjay Mohan
Where
Nashville, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 2
People taking part
1 person enrolled
Started
13 Apr 2023
Ended
20 Sept 2024
Type of study
Interventional
Treatments tested
  • Venetoclax
  • Decitabine
  • Cedazuridine
  • Bone Marrow Aspiration and Biopsy
  • Biospecimen Collection
Record updated
9 January 2026
Why it stopped
Study was terminated early due to lack of accrual and loss of funding.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Age >= 18 years at the time of signing the Informed Consent Form (ICF); must voluntarily sign an ICF and meet all study requirements
  • History of morphologically confirmed AML (per World Health Organization [WHO] diagnostic criteria) with evidence of disease recurrence (>= 5% blasts consistent with prior disease) that occurs after allogeneic hematopoietic cell transplantation (HCT). Patients transplanted for another indication (e.g., myelodysplastic syndrome/chronic myelomonocytic leukemia [MDS/CMML]) who relapse with AML are eligible to enroll
  • White blood cells (WBC) must be less than 25,000/ul for at least three days prior to cycle 1, day 1 (C1D1) (hydroxyurea allowed)
  • A bone marrow biopsy must be performed and tissue collected for entrance to the trial
  • Eastern Cooperative Oncology Group Performance Status of 0 - 2
  • Alanine transaminase (ALT) serum glutamic pyruvic transaminase (SGPT) and/or aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) less than or equal to 3x upper limit of normal (ULN)
  • Total bilirubin < 1.5 x ULN; Patients with Gilbert's syndrome (hereditary indirect hyperbilirubinemia) must have a total bilirubin of < 3 x ULN
  • Calculated creatinine clearance >= 30 ml/min (per the Cockroft-Gault formula)
  • Willingness to abide by all study requirements, including contraception, maintenance of a pill diary, and acceptance of recommended supportive care medications

Who cannot take part

  • Prior relapse or progression while receiving venetoclax or other commercially available or investigational BCL-2 inhibitor
  • Anticancer therapy, including investigational agents =< 2 weeks or =< 5 half-lives of the drug, whichever is shorter, prior to C1D1. (Use of hydroxyurea is permitted)
  • Inadequate recovery from toxicity attributed to prior anti-cancer therapy to =< Grade 1 (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version [v]5.0), excluding alopecia or fatigue
  • Radiation therapy or major surgery within 3 weeks of signing consent
  • Concurrent treatment with a non-permitted concomitant medication
  • Known chronic alcohol or drug abuse
  • Any other condition deemed by the investigator to make the patient a poor candidate for clinical trial and/or treatment with investigational agents
  • History of allogeneic HCT, or other cellular therapy product, within 3 months of signing consent
  • Clinically active acute or chronic graft versus host disease (GVHD). Patients must be off calcineurin inhibitors for at least 4 weeks to be eligible
  • Active, uncontrolled infection. Patients with infection under active treatment and controlled with antibiotics are eligible. Prophylaxis is acceptable
  • Inability to tolerate oral medication, presence of poorly controlled gastrointestinal disease, or dysfunction that could affect study drug absorption
  • Other malignancy IF currently being treated or likely to be treated in next 6 months except for basal or squamous cell carcinoma of the skin or cervical carcinoma in situ
  • Clinically significant cardiovascular disease with major event or cardiac intervention within the past 6 months (e.g. percutaneous intervention, coronary artery bypass graft, documented cardiac heart failure) as determined by the investigator
  • Active documented central nervous system leukemia
  • Pregnancy or breastfeeding females

Where in United States

  • Vanderbilt University/Ingram Cancer CenterNashville, United States

About the trial

What the trial wants to find out

This phase II trial tests how well decitabine and cedazuridine (DEC-C) works in combination with venetoclax in treating acute myeloid leukemia (AML) in patients whose AML has come back after a period of improvement (relapse) after a donor stem cell transplant. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving DEC-C in combination with venetoclax may kill more cancer cells in patients with relapsed AML.

The group in the trial

  • Treatment (Venetoclax, DEC-C)Treatment being tested

    Patients receive venetoclax PO daily for 28 days in a 28-day cycle. Patients receive DEC-C PO daily on days 1-5 of a 28-day cycle. Patients undergo bone marrow biopsy and aspiration and blood sample collection throughout the study.

    Treatment: Venetoclax, Decitabine, Cedazuridine, Bone Marrow Aspiration and Biopsy, and Biospecimen Collection

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 2 Study of Decitabine and Cedazuridine in Combination With Venetoclax for AML Relapse After Allogeneic Hematopoietic Cell Transplantation
Record updated
9 January 2026
Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant (NCT05799079) – Frontlight Research